Preventing sickle cell anemia complications in children screening and treatment for life-threatening problems are far too low
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Preventing sickle cell anemia complications in children screening and treatment for life-threatening problems are far too low

Filetype[PDF-1.63 MB]


English
Details Supporting Files Related Documents You May Also Like

Details:

  • Corporate Authors:
    Centers for Disease Control and Prevention (U.S.). Office of the Associate Director for Communication.
  • Description:
    Sickle cell anemia is the most severe form of sickle cell disease, a group of inherited red blood cell disorders causing unusually shaped, hard, and sticky red blood cells. These cells clump together, blocking blood flow carrying oxygen through the body. Sickle cell anemia, which primarily affects Black or African American people, is associated with a shorter life span and life-threatening complications that can affect all parts of the body. These complications cause pain and suffering. Sickle cell anemia is a common cause of childhood stroke.

    There are screenings and treatments available to ease children’s suffering from sickle cell anemia. Two recommended healthcare measures to prevent complications in children with sickle cell anemia are:

    • Transcranial doppler (TCD) ultrasound screening, which identifies children with increased risk for stroke.

    • Hydroxyurea therapy, which reduces the occurrence of several complications, including severe acute pain episodes and acute chest syndrome, which can result in lung injury and trouble breathing.

    Far too few patients are receiving these potentially lifesaving prevention measures, recommended by an expert panel in 2014. Fewer than half of children aged 2–9 years (47%) and 10–16 years (38%) received a TCD ultrasound screening in 2019. Similarly, less than half of children aged 2–9 years (38%) and slightly over half of children 10–16 years (53%) used hydroxyurea. Managing sickle cell anemia in children is complex. These children face discrimination and multiple barriers to care. Racism and prejudice contribute to and worsen these barriers to care, making it harder to receive quality care. This leads to immense physical, emotional, and mental distress for children and their families.

    Everyone can help improve care for people with sickle cell anemia by taking steps to address racism and prejudice. The healthcare system can promote tailored strategies to reduce barriers and increase TCD screening and hydroxyurea use among children with sickle cell anemia.

  • Subjects:
  • Series:
    CDC Vital signs
  • Document Type:
    Webpage
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

Supporting Files

More +

Related Documents

You May Also Like

Checkout today's featured content at stacks.cdc.gov